Skip to content 
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. more
| Time Frame | LIXT | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -22.76% | 1.44% | -1.15% |
| 1-Month Return | -20.11% | 0.64% | -0.25% |
| 3-Month Return | -25.98% | 7.12% | 1.29% |
| 6-Month Return | -31.05% | 17.76% | 9.28% |
| 1-Year Return | 20.32% | 5.11% | 13.55% |
| 3-Year Return | -62.75% | 18.25% | 67.5% |
| 5-Year Return | -91.07% | 34.89% | 77% |
| 10-Year Return | -82.64% | 142.28% | 266.15% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 3.27M | 6.72M | 6.31M | 5.09M | 3.57M | [{"date":"2020-12-31","value":48.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.91,"profit":true},{"date":"2023-12-31","value":75.74,"profit":true},{"date":"2024-12-31","value":53.16,"profit":true}] |
| Operating Income | (3.27M) | (6.72M) | (6.31M) | (5.09M) | (3.57M) | [{"date":"2020-12-31","value":-326644000,"profit":false},{"date":"2021-12-31","value":-672044500,"profit":false},{"date":"2022-12-31","value":-631148100,"profit":false},{"date":"2023-12-31","value":-509023600,"profit":false},{"date":"2024-12-31","value":-357278900,"profit":false}] |
| Total Non-Operating Income/Expense | 3.12K | (14.74K) | 1.27K | 14.01K | (22.95K) | [{"date":"2020-12-31","value":22.25,"profit":true},{"date":"2021-12-31","value":-105.23,"profit":false},{"date":"2022-12-31","value":9.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-163.85,"profit":false}] |
| Pre-Tax Income | (3.26M) | (6.73M) | (6.31M) | (5.09M) | (3.59M) | [{"date":"2020-12-31","value":-326488200,"profit":false},{"date":"2021-12-31","value":-672839600,"profit":false},{"date":"2022-12-31","value":-631253500,"profit":false},{"date":"2023-12-31","value":-508702900,"profit":false},{"date":"2024-12-31","value":-358596500,"profit":false}] |
| Income Taxes | (1.56K) | 6.79K | (7.82K) | (5.09K) | - | [{"date":"2020-12-31","value":-22.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-115.22,"profit":false},{"date":"2023-12-31","value":-74.99,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | (3.26M) | (6.74M) | (6.30M) | (5.08M) | - | [{"date":"2020-12-31","value":-326332400,"profit":false},{"date":"2021-12-31","value":-673518400,"profit":false},{"date":"2022-12-31","value":-630471400,"profit":false},{"date":"2023-12-31","value":-508193876,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (3.26M) | (6.73M) | (6.31M) | (5.69M) | (3.59M) | [{"date":"2020-12-31","value":-326488200,"profit":false},{"date":"2021-12-31","value":-672839600,"profit":false},{"date":"2022-12-31","value":-631253500,"profit":false},{"date":"2023-12-31","value":-568607800,"profit":false},{"date":"2024-12-31","value":-358596500,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (3.26M) | (6.73M) | (6.31M) | (5.09M) | (3.59M) | [{"date":"2020-12-31","value":-326488200,"profit":false},{"date":"2021-12-31","value":-672839600,"profit":false},{"date":"2022-12-31","value":-631253500,"profit":false},{"date":"2023-12-31","value":-508702900,"profit":false},{"date":"2024-12-31","value":-358596500,"profit":false}] |
| EPS (Diluted) | (0.24) | (0.51) | (0.41) | (2.03) | (1.59) | [{"date":"2020-12-31","value":-24,"profit":false},{"date":"2021-12-31","value":-51,"profit":false},{"date":"2022-12-31","value":-40.8,"profit":false},{"date":"2023-12-31","value":-203.34,"profit":false},{"date":"2024-12-31","value":-159.42,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| LIXT | |
|---|---|
| Cash Ratio | 10.25 |
| Current Ratio | 10.42 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| LIXT | |
|---|---|
| ROA (LTM) | -68.32% |
| ROE (LTM) | -130.06% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| LIXT | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| LIXT | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 12.65 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
| PEG | NM |
Lixte Biotechnology Holdings Inc (LIXT) share price today is $3.02
Yes, Indians can buy shares of Lixte Biotechnology Holdings Inc (LIXT) on Vested. To buy
Yes, you can purchase fractional shares of Lixte Biotechnology Holdings Inc (LIXT) via the Vested app. You can start investing in Lixte Biotechnology Holdings Inc (LIXT) with a minimum investment of $1.
You can invest in shares of Lixte Biotechnology Holdings Inc (LIXT) via Vested in three simple steps:
The 52-week high price of Lixte Biotechnology Holdings Inc (LIXT) is $6.26. The 52-week low price of Lixte Biotechnology Holdings Inc (LIXT) is $0.64.
The price-to-earnings (P/E) ratio of Lixte Biotechnology Holdings Inc (LIXT) is
The price-to-book (P/B) ratio of Lixte Biotechnology Holdings Inc (LIXT) is 12.65
The dividend yield of Lixte Biotechnology Holdings Inc (LIXT) is 0.00%
The market capitalization of Lixte Biotechnology Holdings Inc (LIXT) is $28.02M
The stock symbol (or ticker) of Lixte Biotechnology Holdings Inc is LIXT
Consider the share price of Lixte Biotechnology Holdings Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Lixte Biotechnology Holdings Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Lixte Biotechnology Holdings Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Lixte Biotechnology Holdings Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Lixte Biotechnology Holdings Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Lixte Biotechnology Holdings Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
